The estimated Net Worth of Meghan Scanlon is at least $2.08 Millón dollars as of 1 May 2022. Ms. Scanlon owns over 2,062 units of Boston Scientific stock worth over $2,079,057 and over the last 5 years she sold BSX stock worth over $0. In addition, she makes $0 as Senior Vice President and President y Urology and Pelvic Health at Boston Scientific.
Sign up
Ms. Scanlon BSX stock SEC Form 4 insiders trading
Meghan has made over 17 trades of the Boston Scientific stock since 2020, according to the Form 4 filled with the SEC. Most recently she exercised 2,062 units of BSX stock worth $171,022 on 1 May 2022.
The largest trade she's ever made was exercising 16,450 units of Boston Scientific stock on 24 June 2021 worth over $283,927. On average, Meghan trades about 2,311 units every 35 days since 2020. As of 1 May 2022 she still owns at least 25,067 units of Boston Scientific stock.
You can see the complete history of Ms. Scanlon stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Meghan Scanlon biography
Meghan Scanlon serves as Senior Vice President and President, Urology and Pelvic Health of the Company. Since joining Boston Scientific in 2014 as vice president, global marketing for Endoscopy, she has progressed through roles of increasing responsibility in Urology and Pelvic Health and Endoscopy, and played a significant role in driving and shaping the global commercial organization structures and portfolio innovation strategies for both businesses. Prior to joining Boston Scientific, Ms. Scanlon spent nearly 15 years in leadership roles within the Johnson & Johnson medical device business and started her early career as a design engineer at Gillette. She holds a B.S. in Mechanical Engineering from Tufts University and both her M.B.A. and M.S.M.E. from Massachusetts Institute of Technology.
How old is Meghan Scanlon?
Meghan Scanlon is 47, she's been the Senior Vice President and President y Urology and Pelvic Health of Boston Scientific since 2020. There are 28 older and no younger executives at Boston Scientific. The oldest executive at Boston Scientific Corp. is Yoshiaki Fujimori, 69, who is the Independent Director.
What's Meghan Scanlon's mailing address?
Meghan's mailing address filed with the SEC is C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD, CO, 80112.
Insiders trading at Boston Scientific
Over the last 20 years, insiders at Boston Scientific have traded over $938,841,783 worth of Boston Scientific stock and bought 1,398,972 units worth $16,231,539 . The most active insiders traders include Peter M Nicholas, John E Abele y Michael F Mahoney. On average, Boston Scientific executives and independent directors trade stock every 3 days with the average trade being worth of $4,899,929. The most recent stock trade was executed by Michael F Mahoney on 5 September 2024, trading 162,777 units of BSX stock currently worth $13,212,609.
What does Boston Scientific do?
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments.
What does Boston Scientific's logo look like?
Complete history of Ms. Scanlon stock trades at Boston Scientific y Paragon 28
Boston Scientific executives and stock owners
Boston Scientific executives and other stock owners filed with the SEC include:
-
Michael Mahoney,
Chairman of the Board, President, Chief Executive Officer -
Daniel Brennan,
Chief Financial Officer, Executive Vice President -
Joseph Fitzgerald,
Executive Vice President, President, Interventional Cardiology -
Edward Mackey,
Executive Vice President - Operations -
David Pierce,
Executive Vice President and President, MedSurg and President, Endoscopy -
Michael F. Mahoney,
Chairman, Pres & CEO -
Daniel J. Brennan,
Exec. VP & CFO -
Joseph M. Fitzgerald,
Exec. VP & Pres of Interventional Cardiology -
Edward F. Mackey,
Exec. VP of Global Operations -
Jeffrey B. Mirviss,
Exec. VP & Pres of Peripheral Interventions -
Edward Ludwig,
Lead Independent Director -
Charles Dockendorff,
Independent Director -
David Roux,
Independent Director -
John Sununu,
Independent Director -
Donna James,
Independent Director -
Nelda Connors,
Independent Director -
Ellen Zane,
Independent Director -
Stephen MacMillan,
Independent Director -
Yoshiaki Fujimori,
Independent Director -
John Sorenson,
Senior Vice President - Manufacturing and Supply Chain -
Meghan Scanlon,
Senior Vice President and President, Urology and Pelvic Health -
Scott Olson,
Senior Vice President and President, Rhythm Management -
Maulik Nanavaty,
Senior Vice President and President - Neuromodulation -
Wendy Carruthers,
Senior Vice President - Human Resources -
Desiree Ralls-Morrison,
Senior Vice President, General Counsel, Corporate Secretary -
Jodi Eddy,
Senior Vice President, Chief Information Officer -
Eric Thepaut,
Executive Vice President and President - Europe, Middle East and Africa -
Jeffrey Mirviss,
Executive Vice President and President - Peripheral Interventions -
Ian Meredith,
Executive Vice President, Global Chief Medical Officer -
Arthur Butcher,
Executive Vice President and President, Asia Pacific -
Catherine Jennings,
VP of Global Marketing & New Bus. Devel. of Peripheral Interventions -
Vance R. Brown,
Sr. VP, Gen. Counsel & Corp. Sec. -
Susan Vissers Lisa,
VP of Investor Relations -
Jodi Euerle Eddy,
Sr. VP and Chief Information & Digital Officer -
Jonathan R Monson,
VP, Global Controller & Chief Accounting Officer -
Vance R Brown,
SVP, GC and Corp. Secretary -
Timothy A. Pratt,
EVP & General Counsel -
Supratim Bose,
EVP & President, Asia-Pacific -
Michael P. Phalen,
SVP & President, Endoscopy -
Keith D Dawkins,
Sr. VP, Chief Medical Officer -
Kevin J. Ballinger,
EVP & Pres, Interven Cardio -
Cheryl Pegus,
Director -
David S Wichmann,
Director -
Xin Warren Wang,
SVP and Pres, Asia Pacific -
Peter M Nicholas,
Director -
Kristina M Johnson,
Director -
Nicholas J Jr Nicholas,
Director -
Karen Prange,
SVP&Pres, Uro & Women's Health -
Ernest Mario,
Director -
John E Abele,
Director -
Uwe E Reinhardt,
Director -
Katharine T Bartlett,
Director -
Jean Fitterer Lance,
SVP & Chief Compliance Officer -
Kenneth Pucel,
EVP, Operations -
Bruce L Byrnes,
Director -
John Michael Onuscheck,
SVP & Pres-Neuromodulation -
Jeffrey D Capello,
Chief Accounting Officer -
Otha T. Iii Spriggs,
SVP, Human Resources -
William Kucheman,
SVP & Group President -
John Raymond Elliott,
Director -
Lawrence R Neumann,
SVP and Pres, Emerging Markets -
John B. Pedersen,
Pres,Uro & Women's Health -
Brian R Burns,
SVP - Quality -
Ray J Groves,
Director -
Sam R Leno,
CFO & EVP Finance & IS -
Stephen F Moreci,
Sr. VP, Endosurgery -
Marye Anne Fox,
Director -
Fred Colen,
EVP -
John E Pepper,
Director -
James Gilbert,
EVP -
Donovan Paul,
SVP, Corporate Comm -
David W Mc Faul,
Senior VP International -
Ursula M Burns,
Director -
Warren B Rudman,
Director -
William F Jr Mcconnell,
SVP, Administration CRM -
Donald S Baim,
EVP, Chief Med. & Sci. Officer -
Lucia Luce Quinn,
Exec. Vice President-HR -
James R Tobin,
President & CEO -
Paul W Sandman,
EVP and General Counsel -
Paul A Laviolette,
COO -
Nancy Ann Deparle,
Director -
Joel Lawrence Fleishman,
Director -
David C Habiger,
Director -
Jonathan Monson,
SVP, Global Controller and CAO -
Emily Woodworth,
SVP, Global Controller and CAO -
Jessica L Mega,
Director -
Susan E Morano,
Director